Attached files

file filename
EX-99.1 - PRESS RELEASE - NeurogesX Incdex991.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

September 8, 2011 (September 8, 2011)

 

 

NEUROGESX, INC.

(Exact name of registrant as specified in its charter)

 

 

 

DELAWARE   001-33438   94-3307935

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

2215 Bridgepointe Parkway, Suite 200, San Mateo, California 94404

(Address of principal executive offices, including zip code)

650-358-3300

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 8.01. Other Events.

On September 8, 2011, NeurogesX, Inc. (the “Company”), issued a press release entitled “NeurogesX Submits Supplemental New Drug Application for Qutenza® (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN).” A copy of the press release, dated September 8, 2011, is filed as Exhibit 99.1, to this Current Report on Form 8-K and is incorporated by reference herein. The contents of the press release are deemed to be filed for purposes of the Securities Exchanged Act of 1934, as amended.

 

Item 9.01 Financial Statements and Exhibits.

The following exhibits are filed as part of this Current Report on Form 8-K.

 

Exhibit No.

 

Description

99.1   Press Release entitled “NeurogesX Submits Supplemental New Drug Application for Qutenza® (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN).”


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

NEUROGESX, INC.

By:

 

/s/    STEPHEN F. GHIGLIERI

  Stephen F. Ghiglieri
 

Executive Vice President, Chief Operating Officer

and Chief Financial Officer

Date: September 8, 2011

 

3


EXHIBIT LIST

 

Exhibit No.

 

Description

99.1

  Press Release entitled “NeurogesX Submits Supplemental New Drug Application for Qutenza® (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN).”